This study underscores the pivotal role of TXNDC12 in modulating tumor biology and chemoresistance, positioning the METTL1-TXNDC12-c-Myc axis as a promising target for improving patient outcomes in HNSCC. This evidence concerns the gene TXNDC12 and neoplasm.